The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Common Comorbidities Associated With Recurrent C Difficile Infections
January 20th 2025The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal disorders, and metabolic diseases. Management requires a nuanced, multidisciplinary approach focusing on tailored antibiotic strategies, immunomodulation, comprehensive diagnostics, and personalized treatment plans.
Watch
AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes
January 19th 2025Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.
Read More
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
January 17th 2025Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher health care system expenses. Economic mitigation strategies include implementing early screening programs, improving diagnostic technologies, enhancing medical training, and developing robust health care infrastructure that prioritizes timely patient assessment and intervention.
Watch
Sequencing Considerations in Relapsed/Refractory CLL
January 17th 2025Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.
Watch
Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
Panelists discuss how diagnosing iron deficiency anemia requires comprehensive laboratory testing of iron parameters alongside clinical assessment, emphasizing early detection to prevent complications in patients with common comorbidities like chronic kidney disease, heart failure, and inflammatory bowel disease, where coordinated treatment approaches must balance managing both IDA and the underlying condition.
Watch
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease
January 14th 2025Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.
Read More
Updated Guidelines Allow Men Who Have Sex With Men to Join National Blood Donor Month Efforts
January 14th 2025Men who have sex with men (MSM) can now participate in National Blood Donor Month under the FDA's updated guidelines, marking a crucial step toward addressing blood shortages and promoting inclusivity.
Read More
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Diagnosis of Recurrent C Difficile Infections
January 13th 2025The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions. Definitive diagnosis requires molecular and immunological testing of stool samples to detect toxin genes and active toxin production.
Watch
Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
January 13th 2025The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource utilization while severely compromising patient quality of life through persistent physical symptoms, psychological distress, and substantial social disruptions.
Watch
Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
January 10th 2025Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge gaps. Health systems can mitigate these challenges through targeted educational, technological, and culturally responsive interventions.
Watch
Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
January 10th 2025Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.
Watch